Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) released its resubmitted Monthly Return for Equity Issuer for the period ended 31 August 2026, confirming no changes to its registered or issued share capital during the month and affirming compliance with Hong Kong’s public-float thresholds.

Registered Share Capital • Total registered share capital remained unchanged at 228.83 million shares, each with a par value of RMB 1. • This comprises 34.78 million H-shares listed in Hong Kong and 194.05 million A-shares listed on Shanghai’s STAR Market (stock code 688366).

Issued Shares and Treasury Position • H-shares: Outstanding shares stood at 34.78 million; no treasury shares are held. • A-shares: 194.05 million issued, of which 3.85 million are held as treasury stock, leaving 190.20 million shares in public hands. • Throughout August, neither class of shares recorded issuances, cancellations, conversions, or additional repurchases.

Share Repurchase Status • On 29 May 2026, the company repurchased 607,000 H-shares for cancellation. As of 31 August 2026, these shares remained uncancelled, but no further repurchases occurred in August.

Public Float Compliance • HAOHAI BIOTEC confirmed adherence to the Main Board Rule 13.32B minimum public-float requirement of 5% for PRC issuers with other listed shares.

Capital Management Instruments • The company reported no outstanding share options, warrants, or convertible securities, and disclosed no new share-based agreements during the month.

Administrative Confirmation • The filing, signed by Joint Company Secretary Tian Min on 9 September 2026, asserts full compliance with all applicable listing rules, regulatory obligations, and corporate approvals for the period under review.